-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company submitted a new drug marketing application to the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the indications of telicibizumab injection (GR1802 injection) for moderate and severe atopic dermatitis in adults and was accepted.

Zhitongcaijing·07/16/2026 08:41:05
Listen to the news
Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company submitted a new drug marketing application to the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the indications of telicibizumab injection (GR1802 injection) for moderate and severe atopic dermatitis in adults and was accepted.